Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Updated . What changed?
Pulmonx Corp is an other business based in the US. Pulmonx shares (LUNG) are listed on the NASDAQ and all prices are listed in US Dollars. Pulmonx employs 202 staff and has a trailing 12-month revenue of around USD$31.7 million.
|Latest market close||USD$44.46|
|52-week range||USD$37.64 - USD$52|
|50-day moving average||USD$43.2525|
|200-day moving average||USD$43.2525|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-10-13)||7.52%|
|1 month (2020-09-16)||N/A|
|3 months (2020-07-16)||N/A|
|6 months (2020-04-16)||N/A|
|1 year (2019-10-16)||N/A|
|2 years (2018-10-16)||N/A|
|3 years (2017-10-16)||N/A|
|5 years (2015-10-16)||N/A|
|Revenue TTM||USD$31.7 million|
|Gross profit TTM||USD$22.4 million|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$1.5 billion|
TTM: trailing 12 months
We're not expecting Pulmonx to pay a dividend over the next 12 months.
You may also wish to consider:
Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in Europe, the Middle East, Africa, the Asia-Pacific, the United States, and internationally. Pulmonx Corporation was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. The company was incorporated in 1995 and is headquartered in Redwood City, California.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.